The actual benefit of BETESIL 2.25 mg medicated plaster in the Marketing Authorisation indication is substantial.
Clinical Added Value
no clinical added value
BETESIL 2.25 mg medicated plaster does not offer any improvement in actual benefit (non-existent IAB V) in the treatment strategy for psoriasis and other inflammatory skin disorders that do not respond to less potent corticosteroids.
Listen
